Lucera Erick has filed 51 insider transactions across 5 companies since August 2022.
Most recent transaction: a sale of 5727 shares of Dyne Therapeutics, Inc. ($DYN) on April 01, 2026.
Activity breakdown: 1 open-market purchase and 3 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Dyne Therapeutics, Inc. | $DYN | Lucera Erick | Chief Financial Officer | S | Common Stock | 5727 | $18.64 | 125,373.0000 | 142,824,687 | 4.37% | 0.00% |
| Feb. 12, 2026 | Dyne Therapeutics, Inc. | $DYN | Lucera Erick | Chief Financial Officer | A | Stock Option (Right to Buy) | 105000 | $0.00 | 105,000.0000 | 142,824,687 | 9999.99% | 0.07% |
| Feb. 12, 2026 | Dyne Therapeutics, Inc. | $DYN | Lucera Erick | Chief Financial Officer | A | Common Stock | 65000 | $0.00 | 131,100.0000 | 142,824,687 | 98.34% | 0.05% |
| Dec. 16, 2025 | SAB Biotherapeutics, Inc. | $SABS | Lucera Erick | Not found | A | Stock option (right to buy) | 150000 | $0.00 | 150,000.0000 | 77,863,263 | 9999.99% | 0.19% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 1250 | $0.00 | 0.0000 | 92,794,777 | 100.00% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 1000 | $0.00 | 1,000.0000 | 92,794,777 | 9999.99% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 1000 | $0.00 | 0.0000 | 92,794,777 | 100.00% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 1250 | $0.00 | 1,250.0000 | 92,794,777 | 9999.99% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 1250 | $0.00 | 0.0000 | 92,794,777 | 100.00% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 1250 | $0.00 | 1,250.0000 | 92,794,777 | 9999.99% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 1250 | $0.00 | 0.0000 | 92,794,777 | 100.00% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 1500 | $0.00 | 1,500.0000 | 92,794,777 | 9999.99% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 1500 | $0.00 | 0.0000 | 92,794,777 | 100.00% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 2000 | $0.00 | 2,000.0000 | 92,794,777 | 9999.99% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 2000 | $0.00 | 0.0000 | 92,794,777 | 100.00% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 2250 | $0.00 | 0.0000 | 92,794,777 | 100.00% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 2250 | $0.00 | 2,250.0000 | 92,794,777 | 9999.99% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 3750 | $0.00 | 3,750.0000 | 92,794,777 | 9999.99% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 3750 | $0.00 | 0.0000 | 92,794,777 | 100.00% | 0.00% |
| Nov. 4, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 1250 | $0.00 | 1,250.0000 | 92,794,777 | 9999.99% | 0.00% |
| March 31, 2025 | Dyne Therapeutics, Inc. | $DYN | Lucera Erick | Chief Financial Officer | A | Common Stock | 66100 | $0.00 | 66,100.0000 | 113,121,357 | 9999.99% | 0.06% |
| March 31, 2025 | Dyne Therapeutics, Inc. | $DYN | Lucera Erick | Chief Financial Officer | A | Stock Option (Right to Buy) | 214500 | $0.00 | 214,500.0000 | 113,121,357 | 9999.99% | 0.19% |
| March 26, 2025 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| March 8, 2025 | Editas Medicine, Inc. | $EDIT | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | A | Stock Option (right to buy) | 70000 | $0.00 | 70,000.0000 | 82,976,284 | 9999.99% | 0.08% |
| March 8, 2025 | Editas Medicine, Inc. | $EDIT | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | A | Stock Option (right to buy) | 275100 | $0.00 | 275,100.0000 | 82,976,284 | 9999.99% | 0.33% |
| March 4, 2025 | Editas Medicine, Inc. | $EDIT | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | S | Common Stock | 4109 | $1.71 | 112,720.0000 | 82,976,284 | 3.52% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 30000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 45000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 40000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 25000 | $0.00 | 25,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 25000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 20000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 25000 | $0.00 | 25,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 25000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Options (Right to buy) | 25000 | $0.00 | 25,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 22, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | D | Stock Options (Right to buy) | 25000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 14, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | P | Common Stock | 39266 | $0.40 | 43,608.0000 | 0 | 904.33% | 0.00% |
| July 15, 2024 | SAB Biotherapeutics, Inc. | $SABS | Lucera Erick | Not found | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 5,521,487 | 9999.99% | 0.36% |
| May 20, 2024 | Editas Medicine, Inc. | $EDIT | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | S | Common Stock | 22337 | $5.61 | 116,829.0000 | 0 | 16.05% | 0.00% |
| March 20, 2024 | Beyond Air, Inc. | $XAIR | Lucera Erick | Director | A | Stock Option (right to buy) | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2024 | Editas Medicine, Inc. | $EDIT | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | A | Common Stock | 35300 | $0.00 | 113,200.0000 | 0 | 45.31% | 0.00% |
| March 2, 2024 | Editas Medicine, Inc. | $EDIT | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | A | Stock Option (right to buy) | 106000 | $0.00 | 106,000.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2024 | Editas Medicine, Inc. | $EDIT | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | A | Common Stock | 25966 | $0.00 | 139,166.0000 | 0 | 22.94% | 0.00% |
| Sept. 18, 2023 | Bone Biologics Corp | $BBLG | Lucera Erick | Director | A | Non-Employee Stock Option | 85763 | $0.00 | 88,059.0000 | 0 | 3735.32% | 0.00% |
| May 17, 2023 | Editas Medicine, Inc. | $EDIT | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | A | Stock Option (right to buy) | 155800 | $0.00 | 155,800.0000 | 0 | 9999.99% | 0.00% |
| May 17, 2023 | Editas Medicine, Inc. | $EDIT | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | A | Common Stock | 77900 | $0.00 | 77,900.0000 | 0 | 9999.99% | 0.00% |
| Aug. 23, 2022 | Bone Biologics Corp | $BBLG | Lucera Erick | Director | A | Non-Employee Stock Option | 36845 | $0.00 | 68,516.0000 | 0 | 116.34% | 0.00% |